Resources from the same session
LBA2 - SKYSCRAPER-06: Efficacy and safety of tiragolumab plus atezolizumab plus chemotherapy (tira + atezo + chemo) vs pembrolizumab plus chemotherapy (pembro + chemo) in patients (pts) with advanced non-squamous non-small cell lung cancer (NSq NSCLC)
Presenter: Mark Socinski
Session: Mini Oral session 2
Resources:
Abstract
LBA3 - Perioperative Pembrolizumab (pembro) Plus Neoadjuvant Chemotherapy (chemo) in Early-Stage Non-Small-Cell Lung Cancer (NSCLC): A 4-Year Update of KEYNOTE-671
Presenter: Margarita Majem Tarruella
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2, LBA3, 118MO and 66MO
Presenter: Marcello Tiseo
Session: Mini Oral session 2
Resources:
Slides
Webcast
118MO - Trastuzumab deruxtecan (T-DXd) and pembrolizumab in immuno-oncology (IO)-naive HER2-expressing or HER2-mutant non-small cell lung cancer (NSCLC): Interim analysis of a phase Ib study
Presenter: Antoine Italiano
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
66MO - Durvalumab after radiotherapy (RT) in patients (pts) with unresectable Stage III NSCLC ineligible for chemotherapy (CT): final analysis of the phase 2 DUART study
Presenter: Andrea Riccardo Filippi
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
119MO - Phase I/II trial evaluating the innovative therapeutic cancer vaccine PDC*lung01 in combination with anti-PD-1 in patients (pts) with untreated stage IV non-small cell lung cancer
Presenter: Johan Vansteenkiste
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
Invited Discussant 119MO, 120MO and 175MO
Presenter: Mariana Brandão
Session: Mini Oral session 2
Resources:
Slides
Webcast
120MO - Inupadenant combined with chemotherapy in patients with non-squamous NSCLC progressing on or after immune checkpoint inhibitor therapy: Results from dose-finding part of the A2A-005 trial
Presenter: Kristof Cuppens
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
175MO - Investigating the clinical and immunobiological impact of Orphan Genomic Alterations (OGAs) in advanced NSCLC patients treated with immunotherapy.
Presenter: Alessandra Dodi
Session: Mini Oral session 2
Resources:
Abstract
Slides
Webcast
67MO - Node-sparing modified short-course radiotherapy combined with CAPOX and tislelizumab in patients with MSS/pMMR locally advanced rectal cancer: A multicentre phase II trial (mRCAT)
Presenter: Zhangfa Song
Session: Mini Oral session 2
Resources:
Abstract